Cargando…
Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study
We report data from the final analysis of the Chinese subset of the GIDEON (the Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) study, which evaluated the safety and efficacy of sorafenib in Child-Pugh A, B and C patients with unresectab...
Autores principales: | Ye, Sheng-Long, Chen, Xiaoping, Yang, Jiamei, Bie, Ping, Zhang, Shuijun, Liu, Fengyong, Liu, Luming, Zhou, Jie, Dou, Kefeng, Hao, Chunyi, Shao, Guoliang, Xia, Qiang, Chen, Yajin, Yang, Jijin, Deng, Xiaxing, Liu, Yunpeng, Yuan, Yunfei, Fu, Zhiren, Nakajima, Keiko, Yip, Christina S.M., Lu, Zhengguang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872739/ https://www.ncbi.nlm.nih.gov/pubmed/26735891 http://dx.doi.org/10.18632/oncotarget.6781 |
Ejemplares similares
-
Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study
por: Ye, Sheng-Long, et al.
Publicado: (2018) -
Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data
por: Kim, Do Young, et al.
Publicado: (2016) -
First person – Gideon Hughes
Publicado: (2020) -
Dr. Allen Gideon Tripp
Publicado: (1912) -
Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON
por: Kudo, Masatoshi, et al.
Publicado: (2016)